DataSheet_1: 1型糖尿病血糖监测设备——从FDA批准到市场可及性的旅程
一份关于1型糖尿病血糖监测设备及其FDA批准流程的综述PDF文件。
基本信息
资源简介
DataSheet_1: 1型糖尿病血糖监测设备——从FDA批准到市场可及性的旅程
【一句话概览】
本数据集是 figshare 公开的文本数据集，收录 1 个文件、合计 69.45 KB，主题涵盖 type 1 diabetes、glycemic control、food and drug administration、electrochemical sensors、continuous glucose monitoring devices，可用于医学自然语言处理（实体识别、信息抽取等），CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf》。配套论文《Type 1 diabetes》发表于 The Lancet（2023），DOI：10.1016/S0140-6736%2823%2900223-4。源站首次发布：2024-03-15。
【数据内容】
源站原始描述：Blood glucose monitoring constitutes a pivotal element in the clinical management of Type 1 diabetes (T1D), a globally escalating metabolic disorder. Continuous glucose monitoring (CGM) devices have demonstrated efficacy in optimizing glycemic control, mitigating adverse health outcomes, and augmenting the overall quality of life for individuals afflicted with T1D. Recent progress in the field encompasses the refinement of electrochemical sensors, which enhances the effectiveness of blood glucos…
中文译文（机器翻译，仅供快速理解，请以原文为准）：血糖监测是1型糖尿病（Type 1 diabetes, T1D）临床管理中的关键环节，而T1D是一种全球范围内不断加剧的代谢性疾病。持续葡萄糖监测（continuous glucose monitoring, CGM）设备已显示出在优化血糖控制、减少不良健康结局以及提高T1D患者整体生活质量方面的有效性。该领域近期进展包括电化学传感器的改进，
【数据结构与技术规格】
文件数 1 个，合计 69.45 KB。DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf：application/pdf，69.45 KB。数据集 DOI：10.3389/fendo.2024.1352302.s001。
【主题与分类】
源站学科分类：Reproduction、Cell Metabolism、Endocrinology。主题标签：type 1 diabetes、glycemic control、food and drug administration、electrochemical sensors、continuous glucose monitoring devices、regulatory approval。
【适用方向】
文本类数据可用于医学自然语言处理，如命名实体识别、信息抽取与文本分类。
【获取与许可】
源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Blood_glucose_monitoring_devices_for_type_1_diabetes_a_journey_from_the_food_and_drug_administration_approval_to_market_availability_pdf/25414231
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Mittal, Rahul; Koutras, Nicole; Maya, Jonathan; Lemos, Joana R. N.; Hirani, Khemraj (2024). DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf. Frontiers. Dataset
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf
- DOI：10.3389/fendo.2024.1352302.s001
- 发布日期：2024-03-15
- 文件数：1 个
- 文件总体积：69.45 KB
- 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Blood_glucose_monitoring_devices_for_type_1_diabetes_a_journey_from_the_food_and_drug_administration_approval_to_market_availability_pdf/25414231
命令行下载
curl -L -o "DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf" "https://ndownloader.figshare.com/files/45056380"
文件清单
DataSheet_1_Blood glucose monitoring devices for type 1 diabetes: a journey from the food and drug administration approval to market availability.pdf（69.45 KB）
文件总体积 69.45 KB（源站 API 实测）。
数据说明
Blood glucose monitoring constitutes a pivotal element in the clinical management of Type 1 diabetes (T1D), a globally escalating metabolic disorder. Continuous glucose monitoring (CGM) devices have demonstrated efficacy in optimizing glycemic control, mitigating adverse health outcomes, and augmenting the overall quality of life for individuals afflicted with T1D. Recent progress in the field encompasses the refinement of electrochemical sensors, which enhances the effectiveness of blood glucose monitoring. This progress empowers patients to assume greater control over their health, alleviating the burdens associated with their condition, and contributing to the overall alleviation of the healthcare system. The introduction of novel medical devices, whether derived from existing prototypes or originating as innovative creations, necessitates adherence to a rigorous approval process regulated by the Food and Drug Administration (FDA). Diverse device classifications, stratified by their associated risks, dictate distinct approval pathways, each characterized by varying timelines. This review underscores recent advancements in blood glucose monitoring devices primarily based on electrochemical sensors and elucidates their regulatory journey towards FDA approval. The advent of innovative, non-invasive blood glucose monitoring devices holds promise for maintaining stringent glycemic control, thereby preventing T1D-associated comorbidities, and extending the life expectancy of affected individuals.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fendo.2024.1352302.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Blood_glucose_monitoring_devices_for_type_1_diabetes_a_journey_from_the_food_and_drug_administration_approval_to_market_availability_pdf/25414231）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
